Luiz Gustavo Torres

Medical Oncologist at Oncologia Dor
Focused on Breast Cancer and Oncogeriatrics

[Luiz Gustavo Torres @luiztorresMD]

Today, patients with metastatic cancer face a new perspective: excellent and sustained responses to treatment, which translate into years of quality of life, not just months. Advances in targeted therapies and immunotherapy are transforming what was once considered unattainable, offering real and lasting hope.

[Luiz Gustavo Torres @luiztorresMD]

@adishP Coisa ridicula

[Luiz Gustavo Torres @luiztorresMD]

@Theholisticpsyc Totally!
So glad to hear this!

[Luiz Gustavo Torres @luiztorresMD]

Perda de peso ≠ melhores resultados no tratamento do câncer
⚠️ A perda de peso induzida pelo GLP-1 pode custar massa muscular (até ~40%)
📉 Sarcopenia → fragilidade, piores resultados oncológicos, ↓ sobrevida
🥗🏋️ Nutrição + treinamento de resistência = mais seguro, comprovado e subutilizado
➡️ Primeiro o estilo de vida. Depois os medicamentos

[Paolo Tarantino @PTarantinoMD]

The @US_FDA approves T-DXd/pertuzumab for the first-line treatment of HER2+ metastatic breast cancer, based on the DESTINY-Breast09 trial. Data on the T-DXd monotherapy arm of the study pending and highly awaited. https://t.co/VKRtZgvx8j

[Luiz Gustavo Torres @luiztorresMD]

Preclinical studies show that respiratory viral infections, such as influenza and SARS-CoV-2, can "awaken" dormant tumor cells in the lung in breast cancer models.

🫁 Viral infection generates an inflammatory environment in the lung, particularly via the IL-6 pathway, which promotes the proliferation of these cells and reduces local immune surveillance.

#SABCS25

[Luiz Gustavo Torres @luiztorresMD]

🇧🇷 Câncer de mama inicial HR+/HER2- (Grau 3)
Mundo real no #SABCS25: doença mais avançada guiou o uso de antraciclina, com OR chegando a 9,6 (T3–4; N2–3; Ki67 >20%).
⏳ Apesar disso, a EFS em 2 anos foi semelhante vs. esquemas sem antraciclina.

A discussão permanece aberta.
#BreastCancer #Oncologia #RealWorldData

[Luiz Gustavo Torres @luiztorresMD]

Terrific!!

[Paolo Tarantino @PTarantinoMD]

The billion dollar question: should we sequence ADCs for treating MBC? Proud to join @JoshDragoMD in this @NEJM debate, where we review the data in support and against the sequential use of ADCs. Open access — read it here: https://t.co/Czm66bL7vF

[Paolo Tarantino @PTarantinoMD]

The billion dollar question: should we sequence ADCs for treating MBC? Proud to join @JoshDragoMD in this @NEJM debate, where we review the data in support and against the sequential use of ADCs. Open access — read it here: https://t.co/Czm66bL7vF

[Luiz Gustavo Torres @luiztorresMD]

Um ano “avassalador” de dados em câncer de mama. Thanks @IlanaSchlam

[Ilana Schlam @IlanaSchlam]

In 2025, many important and long-awaited studies were published. I included them but kept the algorithms unchanged, as there are open questions about how these data will impact practice, particularly in early and metastatic HER2+ disease and mTNBC.
@DFCI_BreastOnc #SABCS25

[Ilana Schlam @IlanaSchlam]

In 2025, many important and long-awaited studies were published. I included them but kept the algorithms unchanged, as there are open questions about how these data will impact practice, particularly in early and metastatic HER2+ disease and mTNBC.
@DFCI_BreastOnc #SABCS25

[Luiz Gustavo Torres @luiztorresMD]

Dado muito relevante. Muitas vezes minimizamos o potencial tóxico das associações por falta de dado. Good to see @PTarantinoMD

[Paolo Tarantino @PTarantinoMD]

Can we combine radiotherapy with CDK4/6i, HER2, PARP or mTOR targeted agents? Just out on the green journal the ESMO-ESTRO systematic review (107 studies) and Delphi consensus on the topic. Huge work, masterfully led by Evert van Aken. Read it here: https://t.co/K1lW02TiFL

[Paolo Tarantino @PTarantinoMD]

Can we combine radiotherapy with CDK4/6i, HER2, PARP or mTOR targeted agents? Just out on the green journal the ESMO-ESTRO systematic review (107 studies) and Delphi consensus on the topic. Huge work, masterfully led by Evert van Aken. Read it here: https://t.co/K1lW02TiFL

[Luiz Gustavo Torres @luiztorresMD]

O algoritmo do câncer de mama avançado HR+ está em ebulição!
Extraordinário acompanhar isto.
Congrats ⁦@Sonyareid07⁩

#sabcs25

[Luiz Gustavo Torres @luiztorresMD]

Dado muito aguardado.
PROs do DB-09 semelhante ao braço controle. Pelo menos durante o taxane do CLEOPATRA.
PROs são o presente e o futuro!

#sabcs25

[Luiz Gustavo Torres @luiztorresMD]

Mesas sempre com a presença da voz da paciente. Precisamos ter mais isso no Brasil 🇧🇷
#SABCS25

[Luiz Gustavo Torres @luiztorresMD]

🤯 BREAKING NEWS do #SABCS2025: O FIM DA MAMOGRAFIA ANUAL PARA TODAS?

O Ensaio Clínico WISDOM (com 28 mil mulheres) sacudiu os protocolos de rastreamento do câncer de mama. A medicina de precisão está aqui, e ela é mais segura e inteligente.

[Luiz Gustavo Torres @luiztorresMD]

@SportsCenterBR Traira

[Eric Topol @EricTopol]

Exercising fathers, enhanced endurance and metabolic heath in offspring, through sperm microRNAs (as demonstrated in mice)
https://t.co/Pak45uoWI4

[Luiz Gustavo Torres @luiztorresMD]

Ganho de sobrevida também para quem não recebe IO (PD-L1-).
Nunca tivemos tantas opções para TNBC!